# RHÖN-KLINIKUM AG Conference Presentation

























### **Disclaimer**



This presentation has been prepared by RHÖN-KLINIKUM AG (the "Company") and is for information purposes only.

This presentation does not constitute, or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company, nor shall it or any part of it form the basis of or be relied upon in connection with any contract or commitment whatsoever.

This presentation may contain forward-looking statements relating to the business, financial performance and results of the Company and the industry in which the Company operates. Any forward-looking statements contained in this presentation, including any assumptions, opinions and views of the Company and information attributed to or summarized from third party sources, represent solely opinions and forecasts which are subject to risks and uncertainties. Actual events may differ significantly from current expectations or assumptions due to many factors. The Company does not guarantee that the assumptions underlying the forward-looking statements in this presentation are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecasted developments. The statements in this presentation are made only as of the date of this presentation. The Company does not undertake any obligation to review, update or confirm investors' expectations or estimates or to release publicly any revisions to any forward-looking statements given in this presentation to reflect subsequent events or circumstances that may arise in relation to the content of this presentation. Consequently, neither the delivery of this presentation nor any further discussion of the Company with any of the recipients thereof shall under any circumstances create any implication that there has been no change in the affairs of the Company since such date.

Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

By accepting this presentation you acknowledge the foregoing and that you will be solely responsible for your own assessment of the Company, the industry and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the current and potential future performance of the Company's business.

Glossary: € = Euro; \$ = (US)Dollar; (F)Y = (financial) year(s); M = month(s); % = percentage; a = actual; acc. = according; approx. = approximately; e = expected; k = thousand(s); m = million(s); N/A = not applicable

### **Agenda**






RHÖN-KLINIKUM AG – Agenda

## New RHÖN at a glance Key figures





- ✓ 5 sites = Bad Neustadt, Frankfurt (Oder), Bad Berka, Giessen and Marburg
- ✓ 8 clinics = Bad Berka, Campus Bad Neustadt Acute Care, Campus Bad Neustadt Rehab, Psychosomatic Clinic Bad Neustadt, Haus Saaletal Bad Neustadt (detoxification center), Frankfurt (Oder), University Hospital Giessen and University Hospital Marburg
- √ 7 MVZs (polyclinics) = Bad Berka, Bad Neustadt, Frankfurt (Oder), Weimar, Giessen, Marburg (2x)

## New RHÖN at a glance Market position






#### German hospital market 2)

- Total hospital expenditure ~ €91bn
- 10Y CAGR **+4.2% p.a.**

## Ownership in German hospital market

Total number of beds in the market: 497,182 3)



<sup>1)</sup> Based on number of beds of RHÖN-KLINIKUM/total beds and ø-CMI of ~1.5 per bed

<sup>2)</sup> Based on statutory and private insured patient revenues

<sup>3)</sup> latest available total number of beds in the market as of 2017

<sup>(</sup>Source: Federal Bureau of Statistics Germany, "Grunddaten d. Krankenhäuser", September 18)

### From Old RHÖN to New RHÖN

### The rational behind the deal



### RHÖN-KLINIKUM AG sold 43 clinics in 2014 in an asset deal...

### Old RHÖN

(before Fresenius/Helios Deal)

- 53 individual clinics throughout Germany
- Portfolio: Mass producer, from small county hospital to maximum care provider
- Size: "Huge oil tanker"
- Strategy: Buy financially distressed clinics, restructure them to achieve target margins, potentially sell them
- No overall medical strategy; local focus

STRUCTURAL CHANGE PROCESS

HAS
ALREADY BEEN
COMPLETED

### **New RHÖN**

- 8 clinics in 5 core sites
- All sites above critical bed size (>500 beds)
- Portfolio: Focus on state-of-the-art medicine; treatment of highly severe cases within core business areas
- The only private provider with direct access to university medicine
- Size: "Agile speed boat"
- Strategy: Campus Concept and Digitalisation
- Vision: "Top nodge medical care in rural areas within fully digitalised clinics"





## New RHÖN at a glance Our portfolio



"RHÖN has only system-relevant large sites with more than 500 beds and is therefore less effected by the current structural change in the German hospital market."



- Beds 647
- Patients ~ 114k\*
- Employees ~ 1,900
- Academic teaching hospital of the University Clinic Jena



- Beds 1,522
- Patients ~ 94k\*
- Employees ~ 3,500
- Opening of the first RHÖN Campus
- Academic teaching hospital of Philipps-University Marburg



- Beds 852
- Patients ~ 117k\*
- Employees ~ 1,700
- Conversion of traditional hospital into Campus
- Academic teaching hospital of Charité Berlin



- **2,291** beds
- Patients ~ 525k patients\*
- Employees ~ 9,800
- 3<sup>rd</sup> largest university hospital in Germany
- Sector advantage: Knowledge transfer between RHÖN sites

More than 2/3 of revenue line from growth segments: cardiovascular, oncology, pneumology, neurology, special orthopedics and trauma surgery

\* Including MVZs (polyclinics)

### From Old RHÖN to New RHÖN

### New Management Board



#### Stephan Holzinger (CEO/CFO)

Corporate communications, IR, corporate development, accounting, tax, controlling, corporate finance, HR, legal, data protection, compliance, internal audit, digital transformation and corporate offices

#### Prof. Dr. Bernd Griewing (CMO)

Medical board, patient safety, quality management and hygiene, medical process management, network medicine, innovations and clinical sites Bad Neustadt and Frankfurt (Oder)

#### Dr. Gunther K. Weiß (COO)

Procurement management, construction and technology, IT and clinical sites Bad Berka,

Giessen and Marburg



# Company's strategic direction Moving ahead after the transformation





**Campus** strategy

Unique cross-sectoral care model 1st Campus established at Bad Neustadt



Digitalisation strategy

Tiplu (Semantic Coding Assistance)
Medical Cockpit, digital patient file, et al.

### THE NEW RHÖN



"In comparison to other private operators, RHÖN has already completed the transformation process and is thus less effected by the current structural change in the German hospital sector!"

Stephan Holzinger, CEO/CFO



Expansion strategy

Domestic Campus rollout Business opportunities abroad




Optimisation of value chain

Telemedicine, short-term care and further measures to improve and expand the overall treatment process

### Pillar 1: Campus strategy


### Our solution: The healthcare Campus of the future





### Pillar 2: Expansion strategy Rollout of Campus Concept





### **Pillar 3: Digitalisation**

### Digital tools



#### **Digital clinical processes**

- Mobile doctor's visit
- Medical Cockpit
- Digital self-anamnesis
- Digital medical archive
- Digital nurse call center
- Online appointments
- Digital patient files
- Medical expert database
- ٠..

### Digital admin processes

- Semantic coding assistance
   →Tiplu Momo
- Digital picking of medical supplies and requests from individual wards
- E-Learning
- Digital invoice processing & accounting

## DIGITAL

**TOOLBOX** 

based on a modern and performance orientated IT-infrastructure

## Communications & data transfer

- "Physician's Portal"
- Medical image data exchange and teleradiology
- Tele-stroke, tele-monitoring and tele-councils
- Video communication and video consultation hours
- •

#### State-of-the-art medtech

- Hybrid operating theatres with video management systems and imaging technologies
- SPM = surgical procedure manager (navigation system for surgery rooms)
- DaVinci (surgery robotic)
- Robot assisted X-ray systems
- **Exoskeletons** (walking support robots)

...

Taking into account current data protection guidelines and the DSGVO

### Pillar 4: Optimisation of value chain

### Additional growth opportunities for RHÖN



#### Telemedicine before outpatient care, inpatient care and rehab

- Telemedicine as a reasonable addition to our hospital business ahead of the existing value chain
- Cooperation with Swiss telemedicine pioneer Medgate
- RHÖN-KLINIKUM AG holds the majority of New-Co "Medgate Deutschland" with 51%, Medgate holds a 49% stake
- Medgate Deutschland will in future offer access to medical advice and treatment for both urgent and/or general medical questions via telephone, video, internet and smartphone app irrespective of time or place




Source: Medgate



Source: Medgate

### **Agenda**





RHÖN-KLINIKUM AG – Agenda 14

### Campus Bad Neustadt



#### 12/2018 - Opening of the new Campus Bad Neustadt

- One of the largest individual construction projects in the company's 45-year history
- Ideal implementation of the Campus Concept for holistic health care in rural areas for the first time

## 12-2018/01-2019 – Successful relocation of the Bad Neustadt clinics to the new Campus

- Bundling of medical excellence on Campus
- Optimization of patient control through centralization

#### **Digital high-end solutions**

- 16 operating theatres, including 2 hybrid operating theatres
- Robot-based X-ray system with 3D imaging
- Equipment of all theatres with complex video management systems
- Two of the most powerful CT's (computer tomographs)
- State-of-the-art app-controlled exoskeleton for stroke patients
- Use of digital solutions such as Medical Cockpit and "Physician's Portal"







### Frankfurt (Oder)



#### Strategic realignment of Health Campus Frankfurt (Oder)

- At our Frankfurt (Oder) site a second health Campus is being built
- Center for Outpatient Medicine
  - Cooperations e.g. standby doctor's office, MVZ, therapy offices
  - 18 practices on the Campus
  - ➤ 180,000 contacts to patients a year

#### Geriatric traumatology offers new care concept

Geriatric trauma center at the hospital established in January 2019

#### State-of-the-art computer tomography for better diagnostics

 Institute for Radiology and Interventional Neuroradiology puts one of the world's most modern computer tomographs into operation

#### Outlook 2019/2020 – Focus on the following medical centers

- Vascular Medicine
- Cardiac Medicine with Cardiac Surgery
- Neuro Medicine
- Geriatric Medicine
- Mental Health







### Bad Berka



#### 120 years of clinical medicine

 With the establishment of the former lung sanatorium, the foundation stone was laid for today's top medicine provider of Bad Berka

#### 45 years interdisciplinary cardiac center

- One of the largest and best recognised heart centers in Germany
- Interdisciplinary network of cardiac surgery, cardiology and electrophysiology with a catchment area extending far beyond the region

#### 25 years of spinal surgery

- One of the largest spine departments in Germany
- Known beyond national borders in the context of serious accidents

#### 20 years paraplegic center

- Supraregional leader regarding the care of paraplegic patients
- Only paraplegic center in the whole of the state Thuringia

#### 20 years PET center and clinic for radiopharmacy

- One of the most modern clinics for radiopharmacy in Europe with operation of its own cyclotron system
- Leading in personalized radiopharmaceutical tumor therapy (Theranostics)







### University Hospital Giessen



#### Cardio-lung cluster of excellence "Cardio-Pulmonary System" (ECCPS)

- Only cluster of excellence for heart and lung research in Hesse remains a stable factor
- Unique selling proposition throughout Germany

#### **Foundation of the Intergenomics Network**

- Center for Integrated Genome Medicine for innovative diagnostics and personalized treatment of cancer in children and adults
- Revolution in oncology: liquid biopsy

#### **Progress in Med-tech equipment**


- New low-radiation children's heart catheter measuring station in the children's heart center
- SPECT-CT Hybrid System in nuclear medicine
- Robot assisted operations (DaVinci) of the latest generation

#### **University Medical Outpatient Center**

- Interdisciplinary outpatient center with its own range of outpatient services, private practices and day clinics
- Expansion of the range of services and use of the network for referrals
- Part of the holistic cross-sector Campus model of RHÖN-KLINIKUM AG







### **University Hospital Marburg**



## RHÖN-KLINIKUM AG secures the future of the Marburg Particle Therapy Center (MIT)

- Acquisition of the majority interest in MIT from Heidelberg University Hospital (75.1%)
- Introduction of a successful new chapter for MIT
- Positive signal for the Marburg site, UKGM, Central Hesse and our patients

#### Successful start of the "Physician's Portal"

- Patients benefit from the expansion of the digital networking of the University Hospital Marburg by prompt transmission of their discharge letters to the physicians in private practices who continue treating them
- High acceptance: More than 96% of the patients invited already agreed to participate in the "Physician's Portal" during inpatient admission

#### A new era in cancer immunotherapy

- Breakthrough in cancer treatment with tailored immune cells for specific hematological tumor diseases
- With the so called CAR T cell Therapy, the University Hospital Marburg is one of the few centers in Europe that can offer this high-innovative therapy







## New separate accounting contract

### The pact for the future



## "Groundbreaking agreement on the separate accounting signed with the State of Hesse in 2017, contract in force!"

- New separate accounting contract became effective in Q3 2018 after third party comparison on a arm's length principle by KPMG was finished
- For the first time RHÖN is adequately compensated for it's research and teaching efforts
- +€11.6m extra contribution on EBITDA (ongoing effect), thereof...
  - +€7.4m recorded under other income
  - ✓ -€4.1m booked against personnel expenses
- +€20m one-off effect, thereof...
  - +€12.8m recorded under other income
  - ✓ -€7.2m booked against personnel expenses
- Contract includes an annual increase by +2.5% (base year 2017)
- ► UKGM sustainably strengthened with strategically important €100m capex program (incl. €13m grant from State of Hesse)
- > The program runs until the end of 2021 and has the potential of being established as a permanent solution beyond that



**UKGM (Giessen site)** 



**UKGM (Marburg site)** 

### **Agenda**





RHÖN-KLINIKUM AG – Agenda 21

### **Financials**

### FY 2018 key figures



#### Volumes

- +1.6% more treated patients
- Total number of cases 850,147
- Reduced number of inpatient cases (-0.4%) outperformed by increased number of ambulatory treatments (+2.3%)


### Earnings & Cash

**EBIT** (last year) **€64.9m** (€38.7m)


Net Profit (last year) €51.2m (€36.7m)

Cash **€246.7m** 

#### Revenues



#### **EBITDA**



<sup>\*</sup> Includes a +€20m one-off from separate accounting

<sup>\*\*</sup> Adjusted for effects from the settlement of additional fees for Spinraza; unadjusted EBITDA margin 10.2%

### 9M 2019 results

### Highlights



### Compelling a challenging market environment

- Revenue growth of +4.6% with +0.5% more treated patients in first nine months of 2019
- EBITDA margin at 10%; but EBITDA as expected down by -4.9% (yoy) due to various contrary effects\*
- Excessive regulation and bureaucratization by the legislator, hot summer and Campus Bad Neustadt
   ramp-up effects weigh on business
- Operational challenges at all our locations are addressed, but will take more time for earnings effects to materialize
- Highly specialized acute care offers, unique cross-sectoral Campus model, sharpening of classical hospital processes, digitalization and telemedicine as key strategic solutions to excel
- Invest, strategy and finance committee on behalf of the supervisory board of RHÖN-KLINIKUM AG approved the establishment of Medgate Deutschland GmbH\*\*

<sup>\*</sup> Detailed explanation next to the P&L on page 5

<sup>\*\*</sup> RHÖN is the majority holder of new co. with 51%;
Approval after reporting period ending 30 Sept. 2019

### **Extended improvement program**

### Further measures to improve our performance





- Ensuring optimal bed occupancy, length of stay and discharge management
- Establishment of command and control tools for chief physicians and hospital managers



- Triage and control of patients flows with additional support by new tele medical offers
- Integrative and cross-sector approach per site further developed:
   Telemedicine, before outpatient medicine, before acute inpatient medicine and rehab
- Retention and further recruitment of skilled personnel in all medical areas



- Pursuit of alternative reimbursement models at regional levels based on prevention
- Improvement of revenues through the group-wide application of an AI-assisted coding software

### **Key P&L figures**

### First Nine Months of 2019



Performance* in € millions	9M 2019		vs. 9M 2018	
Revenue	970.8	100.0%	4.6%	
Other income	168.6	17.4%	25.4%	
Material exp.	-300.1	30.9%	7.5%	6
Personnel exp.	-644.1	66.4%	8.6%	
Other exp.	-97.5	10.1%	10.7%	
EBITDA	97.5	10.0%	-4.9%	/0
D&A	-51.7	5.3%	14.1%	
EBIT	45.8	4.7%	-19.9%	
Financial result	-1.8	-0.2%	>-100%	\ \
Income taxes	-6.2	0.6%	-31.1%	0
Consolidated profit	37.8	3.9%	-20.6%	

#### Detailed explanation of P&L effects

Besides price-volume-effects and regulatory interventions, revenues are impacted by a stronger case-severity-mix in acute-care areas, CAR T-Cell therapy and higher negotiated receipts for university ambulance centers

Other income is driven by a +€30m provision release from lapsed warranties of the Helios transaction, additional income for MS treatments and compensations for the education of health students

Increase in material expense is mainly affected by more cost-intensive services and extra costs for treatments of MS and CAR T-cell therapy

A higher head-count, tariff agreement pay rises, share-based payments to former mgmt board members and salaries for health students which are fully reimbursed under other income are impacting personnel costs

EBITDA percentage decrease influenced by above described P&L effects and a €20m one off from separate accounting in 2018


Increased D&A based on commissioning of Bad Neustadt campus and application of new leasing standard (IFRS 16)

Newly emitted registered bond (2019) and promissory loan note (2018) result in higher interest expenses

\* Fully detailed and comprehensive P&L in 9M 2019 report

# Core balance sheet positions as of 30 September 2019





## RHÖN shows a strong financial solvency, solid balance sheet ratios...

- High Equity ratio of 72%
- Net Liquidity of €+72m
- Net Debt/EBITDA <0</p>

## and a well coordinated multi-stage financial strategy...

- 2017 revolving loan facility of €100m (not drawn by 30 September 2019)
- ≥ 2018 promissory loan notes of €100m (Schuldscheindarlehen: 5, 7 and 10 year tranches)
- 2019 registered bonds of €60m (Namensschuldverschreibung: maturity of 20 years)

### Outlook





#### **Guidance confirmation**

GUIDANCE 2019 **Group REVENUES** 

€ 1.30bn +/- 5%

**Group EBITDA** 

€ 117.5m to € 127.5m

fully confirmed


### **Regulatory environment in 2020**

- DRG price inflator at 3.66% for 2020\*; Fixed cost degression discount set to be at -35% (no changes to 2019)
- Minimum staffing levels in nursing care also relevant for heart surgery and neurology wards incl. stroke units
- €500m nursing allowance "Pflegezuschlag" to be abolished, €200m to be transferred to the fed. base rate (+0.30%)
- Effects of new nursing regulation expected to be in the low € double-digit million range for RHOEN in 2020

<sup>\*</sup> Final DRG inflator expected to be lower due to negotiations on individual state levels

### **Agenda**





RHÖN-KLINIKUM AG – Agenda

### Staffing policy

### Recruitment offensive for nursing care



#### **Incentives**

- 2018 Start of an exchange program for nursing students between Bad Berka and the University Hospital Marburg
- Assistance in finding accommodation and discounted offers
- Support in finding kindergartens and nursery spaces
- Parcel and grocery delivery directly to the workplace (DHL/Amazon lockers)

#### **Differentiated patient communications**

- Patient needs and tasks are digitally recorded, prioritized and transmitted in a structured way to the ward staff
- More efficient communication between nurses and patients
- Multilingual system used at UKGM; well accepted by staff and patients

#### **Group-wide nursing integration program**

- Program established in Bad Neustadt for the recruitment and integration of nurses from abroad; More than 70 nurses have been recruited in 4 years to date
- Ongoing transition of this programme to other sites

#### **Nursing Care Summit**

 First Group-wide nursing summit for interdisciplinary dialogue and adoption of packages of measures to strengthen nursing care



### **Appendix**

### DRG price regulation in 2020 at a glance



#### Federal Level

Layer  $\blacksquare$ 

#### Total hospital system budget

- Wage sum increase as main reference number for DRG inflation in 2020: +3.66%
- Sector-specific cost index +2.99%
- Abolition of nursing allowance ("Pflegezuschlag") leads to further DRG inflation of +0.30% in 2020

#### State Level

.ayer

#### Base rates and case-mix volume for each state

- Negotiations between hospital association and statutory health insurance funds
- Effective price hike depends on regional distribution

#### Hospital Level


**3** 

#### Individual hospital volumes and reimbursement


- Negotiation of volume "budgets" between hospital and health insurance funds
- Additional volumes within the budget reimbursed at 65% for 3 years (→ e.g. Ø-vol. growth assumption of +1.5% p.a. leads over 3Y to a revenue discount of approx. -1.6% for these underlying DRG cases)
- Volumes outside the budget reimbursed at only 35%

#### Average base rate increase in states with RHÖN hospitals





#### Reimbursement in % of base rate




### Appendix Shareholder base



### **Shareholder structure**

as of **30 September 2019**, according to the most recent notifications of voting rights at that time



<sup>\*</sup> Shareholders with less than 3% of total voting rights

### **Appendix**

### IR contact & financial calendar 2020



#### Financial calendar 2020

Conference call

**Preliminary results for FY 2019** 

			Conference call
IR contact  Julian Schmitt  Head of Investor Relations & Treasury  tel +49 9771 65 1536  email ir@rhoen-klinikum-ag.com		24 March 2020	Publication of annual financial report 2019 Annual press conference
	7 May 2020	Publication of Q1 financial report 2020	
	3 June 2020	Annual General Meeting	
		6 August 2020	Publication of H1 financial report 2020
		6 November 2020	Publication of Q3 financial report 2020

21 February 2020